Navigation Links
PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
Date:8/10/2009

SOUTH PLAINFIELD, N.J., Aug. 10 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

The collaboration began in March of 2006 based on PTC's HCV efforts that were initiated using the GEMS(TM) technology (Gene Expression Modulation through Small Molecules). Under the terms of the collaboration, PTC and Schering-Plough are conducting a joint research program and Schering-Plough will be responsible for development and commercialization efforts worldwide. Schering-Plough made an upfront payment of $12 million in 2006 and PTC may earn additional milestone payments if specific development, regulatory and commercial goals are achieved. Total payments to PTC could exceed $200 million. Schering-Plough will receive exclusive worldwide commercialization rights for any approved products and pay PTC royalties on worldwide net sales.

"This important milestone represents the third development candidate arising from our novel technologies and research efforts and demonstrates PTC's ability to identify potential treatments across multiple therapeutic areas. We are very gratified to reach this milestone with Schering-Plough, a recognized leader in antiviral research and a wonderful partner to PTC," said Stuart Peltz, Ph.D., president and CEO of PTC Therapeutics. "Hepatitis C is an area of great unmet medica
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
2. The Breast Cancer Therapeutics Market in Australia
3. Amicus Therapeutics Announces Second Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
5. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
9. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
10. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
11. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , 77.6.6 Sample cooling and subsequent PCR ... samples should remain cooled until the PCR takes place, the , thermoblock must ... , , ... Adapt an initial program and connect via a "LINK" command. , ...
... , , , 7.6.2 Hot Start PCR , ... to interrupt the program. The most-recently , entered temperature is , ... as required. After confirmation by , pressing ... , The "Hold" command enables all possible temperatures to be maintained ...
... , , , , Vincent ... Westbury, New York , , , ... Perhaps the most critical parameter for successful , PCR is ... primer can result in a PCR reaction that will not work. The primer sequence , ...
Cached Biology Technology:7 Programming 2General Notes on Primer Design in PCR* 2General Notes on Primer Design in PCR* 3General Notes on Primer Design in PCR* 4General Notes on Primer Design in PCR* 5General Notes on Primer Design in PCR* 6
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
(Date:4/23/2014)... who have had a stroke, often suffer motor deficits ... study conducted in Taiwan, that will be published in ... is currently freely available on-line as an unedited early ... one group of stroke victims had their own peripheral ... and a similar group did not, those who received ...
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
Breaking Biology News(10 mins):Picky male black widow spiders prefer well-fed virgins 2Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2
... eye following even a mild traumatic brain injury. While the ... Nature suggest that the brain,s protective coverings may ... newly developed mouse trauma model, senior author Dorian McGavern, Ph.D., ... (NINDS), part of the National Institutes of Health, watched specific ...
... other small items to freezing temperatures may be a viable ... However, a new study has found that bed bugs may ... In an article in the Journal of Economic Entomology ... for Control," the authors describe how exposing bed bugs to ...
... monoclonal antibody called gemtuzumab combined with standard chemotherapy has ... and increase rates of disease-free survival in pediatric patients ... a major indicator of potential for long-term survival in ... evaluated a total of 1,022 children averaging 10 years ...
Cached Biology News:Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3Targeted treatment can significantly reduce relapse in children with AML leukemia 2
... is a highly compact, extremely reliable and easy ... and one hi-lo range switch control the output, ... 20 to 250 volts. One two-position switch toggles ... to output current. For maximum safety, the EC105 ...
...
... highly purified preparation qualified to specifically cleave ... preparation is functionally tested for activity with ... contaminating proteases. Prepared from human plasma that ... be negative for HBsAg and for antibodies ...
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
Biology Products: